No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

References

• WildS, RoglicG, GreenA, SicreeR, KingH. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi:10.2337/diacare.27.5.104715111519
   PubMed Web of Science ®Google Scholar
• YoonKH, LeeJH, KimJW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1688. doi:10.1016/S0140-6736(06)69703-117098087
   PubMed Web of Science ®Google Scholar
• BarnesAS. The epidemic of obesity and diabetes: trends and treatments. Tex Heart Inst J. 2011;38(2):142–144.21494521
   PubMed Web of Science ®Google Scholar
• KimMK, KoSH, KimBY, et al. 2019 clinical practice guidelines for type 2 diabetes mellitus in Korea. Diabetes Metab J. 2019;43(4):398–406. doi:10.4093/dmj.2019.013731441247
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2020 abridged for primary care providers. Clin Diabetes. 2020;38(1):10–38. doi:10.2337/cd20-as0131975748
   PubMedGoogle Scholar
• Doyle-DelgadoK, ChamberlainJJ, ShubrookJH, SkolnikN, TrujilloJ. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American diabetes association’s standards of medical care in diabetes clinical guideline. Ann Intern Med. 2020;173(10):813–821. doi:10.7326/M20-247032866414
   PubMed Web of Science ®Google Scholar
• GarberAJ, HandelsmanY, GrunbergerG, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107–139.32022600
   PubMed Web of Science ®Google Scholar
• SanoM. A paradigm shift in the treatment of type 2 diabetes and heart failure. J Atheroscler Thromb. 2020;27(8):727–731. doi:10.5551/jat.RV1704232595185
   PubMed Web of Science ®Google Scholar
• RashidM, ShahzadM, MahmoodS, KhanK. Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. Pak J Med Sci. 2019;35(1):71–76. doi:10.12669/pjms.35.1.10030881399
   PubMed Web of Science ®Google Scholar
• ScheenAJ. Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management … and potentially beyond. Ann Transl Med. 2019;7(Suppl 3):S132. doi:10.21037/atm.2019.05.8231576339
   PubMed Web of Science ®Google Scholar
• PereiraMJ, ErikssonJW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230. doi:10.1007/s40265-019-1057-030701480
   PubMed Web of Science ®Google Scholar
• MinzeMG, WillKJ, TerrellBT, BlackRL, IronsBK. Benefits of SGLT2 inhibitors beyond glycemic control - a focus on metabolic, cardiovascular and renal outcomes. Curr Diabetes Rev. 2018;14(6):509–517. doi:10.2174/157339981366617081614235128814245
   PubMed Web of Science ®Google Scholar
• FramptonJE. Empagliflozin: a review in type 2 diabetes. Drugs. 2018;78(10):1037–1048. doi:10.1007/s40265-018-0937-z29946963
   PubMed Web of Science ®Google Scholar
• IngelheimB. Jardiance^®(Empagliflozin) Prescribing Information. CT USA: US Food and Drug Administration; 2016.
   Google Scholar
• ErdmannE, CharbonnelB, WilcoxR. Thiazolidinediones and cardiovascular risk-a question of balance. Curr Cardiol Rev. 2009;5(3):155–165. doi:10.2174/15734030978897033320676274
   PubMedGoogle Scholar
• KwonMJ, LeeYJ, JungHS, et al. The direct effect of lobeglitazone, a new thiazolidinedione, on pancreatic beta cells: a comparison with other thiazolidinediones. Diabetes Res Clin Pract. 2019;151:209–223. doi:10.1016/j.diabres.2019.04.00630954516
   PubMed Web of Science ®Google Scholar
• Pharm CKD. Duvie Tab. (Lobeglitazone Sulfate) Prescribing Information. Republic of Korea: Ministry of Food and Drug Safety; 2013.
   Google Scholar
• KimJW, KimJR, YiS, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther. 2011;33(11):1819–1830. doi:10.1016/j.clinthera.2011.09.02322047812
   PubMed Web of Science ®Google Scholar
• ParkMK, KimTE, KimJ, et al. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014;34(7):467–474. doi:10.1007/s40261-014-0197-y
   Web of Science ®Google Scholar
• HanE, ShinE, KimG, et al. Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2018;9:412. doi:10.3389/fendo.2018.0041230072956
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drugs Evaluation Research. Guidance for Industry: Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. Maryland: US Food and Drug Administration; 2020.
   Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.28105324141714
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for good clinical practice E6 (R2). J Eur Med Agency. 2016.
   Google Scholar
• ZhangL, ReynoldsKS, ZhaoP, HuangSM. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol. 2010;243(2):134–145. doi:10.1016/j.taap.2009.12.01620045016
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Research CfDE. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. Maryland: US Food and Drug Administration; 2001.
   Google Scholar
• ChiarelliF, Di MarzioD. Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag. 2008;4(2):297–304. doi:10.2147/VHRM.S99318561505
   PubMedGoogle Scholar
• BermudezV, FinolF, ParraN, et al. PPAR-γ agonists and their role in type 2 diabetes mellitus management. Am J Ther. 2010;17(3):274–283. doi:10.1097/MJT.0b013e3181c0808120216208
   PubMed Web of Science ®Google Scholar
• De VosP, LefebvreAM, MillerSG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest. 1996;98(4):1004–1009. doi:10.1172/JCI1188608770873
   PubMed Web of Science ®Google Scholar
• OakesND, ThalenPG, JacintoSM, LjungB. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes. 2001;50(5):1158–1165. doi:10.2337/diabetes.50.5.115811334421
   PubMed Web of Science ®Google Scholar
• LeeJH, NohCK, YimCS, et al. Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats. J Pharm Sci. 2015;104(9):3049–3059. doi:10.1002/jps.2437825648999
   PubMed Web of Science ®Google Scholar
• HsiaDS, GroveO, CefaluWT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73–79. doi:10.1097/MED.000000000000031127898586
   PubMedGoogle Scholar
• ScheenAJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53(3):213–225. doi:10.1007/s40262-013-0126-x24430725
   PubMed Web of Science ®Google Scholar
• SarashinaA, KoiwaiK, SemanLJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28(3):213–219. doi:10.2133/dmpk.DMPK-12-RG-08223149871
   PubMed Web of Science ®Google Scholar
• SemanL, MachaS, NehmizG, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2(2):152–161. doi:10.1002/cpdd.1627121669
   PubMed Web of Science ®Google Scholar
• HeiseT, SemanL, MachaS, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4(2):331–345. doi:10.1007/s13300-013-0030-223838841
   PubMed Web of Science ®Google Scholar
• CahnA, CefaluWT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(Suppl 2):S137–S145. doi:10.2337/dcS15-300727440826
   PubMed Web of Science ®Google Scholar
• DefronzoRA, TripathyD, SchwenkeDC, et al. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes. 2013;62(11):3920–3926. doi:10.2337/db13-026523863810
   PubMed Web of Science ®Google Scholar
• KahnSE, HaffnerSM, HeiseMA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. doi:10.1056/NEJMoa06622417145742
   PubMed Web of Science ®Google Scholar
• BaronKT, MachaS, BroedlUC, NockV, RetlichS, RiggsM. Population pharmacokinetics and exposure-response (efficacy and safety/tolerability) of empagliflozin in patients with type 2 diabetes. Diabetes Ther. 2016;7(3):455–471. doi:10.1007/s13300-016-0174-y27312794
   PubMed Web of Science ®Google Scholar